Moderna Inc. (MRNA)

NASDAQ: MRNA · USD

$214

+6.26 (+3.0%)· Recorded snapshot

영어 원본으로 대체KO

번역하는 동안 영어 원본을 표시 중

이 리포트는 아직 번역되지 않았습니다. 번역 대기열이 따라잡으면 몇 분 후에 새로고침하세요.

StockMarketAgent Research · Analyzed 2026-05-13

Our latest published analysis: MRNA rated Hold

Moderna Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$58.3 / share

Potential value

$78.8 / share

Upside to FV

+9.4%

from $214

Moat

3/10

None

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$21.1B
Revenue (ttm)	2.2B
Net income (ttm)	-3.2B
EPS (ttm)	-$8.01
Shares out	399.2M
Volume	10,987,308
Beta	1.09

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 2.2B
Net income (ttm): -3.2B
EPS (ttm): -$8.01
Market cap: $21.1B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$17.74B	$18.88B	$6.75B	$3.20B	$1.92B	-42.6%
Gross profit	$15.12B	$13.46B	$2.06B	$1.74B	$1.05B	-48.6%
Operating income	$13.30B	$9.42B	$-4.24B	$-3.58B	$-2.76B	—
Net income	$12.20B	$8.36B	$-4.71B	$-3.56B	$-2.82B	—
EPS (diluted)	$28.29	$20.12	$-12.33	$-9.28	—	—
EBITDA	$13.53B	$9.77B	$-3.62B	$-3.39B	$-2.54B	—
R&D	$1.99B	$3.30B	$4.85B	$4.54B	$3.13B	+12.0%
SG&A	$567.0M	$1.13B	$1.55B	$1.17B	$1.02B	+15.8%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AI	C3.ai, Inc.	2B	—	8.4x	-35.6%	+3.6%	-33.6%	매도
BAX	Baxter International Inc.	13.1B	—	1.2x	6.8%	-1.2%	+9.9%	매수
CNC	Centene Corporation	33.2B	22.7x	0.2x	6.9%	+9.6%	+101.2%	비중 축소
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	매도
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	비중 축소
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	비중 축소

Base and Bull scenarios

Bull25%

Price target

$78.75

+47.8% from spot

The mRNA platform's speed and adaptability result in best-in-class efficacy for multiple latent virus and oncology targets. MRNA establishes a broad, highly profitable commercial portfolio, driving revenues back toward $10B+ with 70%+ gross margins and substantial operating leverage.

Broad adoption of CMV vaccine
Personalized oncology success
Terminal EV/Rev expands beyond 8x

Base45%

Price target

$58.30

+9.4% from spot

Moderna undergoes a high-risk transition, absorbing multi-billion dollar operating losses to sustain its $3.1B R&D engine. The validated mRNA platform produces sufficient new blockbusters to return to revenue growth and reach steady-state profitability by the end of the decade.

RSV scales modestly
R&D pipeline yields 1-2 successes
Terminal EV/Rev of 8.0x

Sensitivity: Ke × terminal growth

Ke ↓ / g →	2.0%	2.5%	3.0%	3.5%	4.0%
7.5%	$68.8	$75.7	$84.0	$94.5	$102
8.5%	$58.3	$63.1	$68.8	$75.7	$84.0
9.5%	$50.6	$54.2	$58.3	$63.1	$68.8
10.5%	$44.6	$47.4	$50.6	$54.2	$58.3
11.5%	$40.0	$42.2	$44.6	$47.4	$50.6

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E0

P25 n/aP50 n/aP75 n/a

Trailing P/E0

P25 n/aP50 n/aP75 n/a

ROE-39

P25 n/aP50 n/aP75 n/a

ROIC-76

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All MRNA indicators

Market & fundamental data

Available fields

214

Groups with data

Currency

USD

Showing 214 of 214 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001682852
Company name	Moderna, Inc.
Country	United States
Country code	US
CUSIP number	60770K107
Earnings date	2026-11-06
Earnings time	bmo
Employees	4,700
Employees change	-1,100
Employees growth	-18.97%
Enterprise value	$79.9B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2010
In index	SP500, NASDAQ100
Industry	Biotechnology
IPO date	2018-12-07
Is primary listing	Yes
Is SPAC	No
ISIN number	US60770K1079
Last 10-K release date	2026-02-20
Last earnings date	2026-07-31
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$85.5B
Market cap category	Large-Cap
Next earnings date	2026-11-06
Options	Yes
Price	$214.24
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	MRNA
U.S. state	Massachusetts
Website	https://www.modernatx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-3.74%
EV/Sales	36.13x
FCF / EV yield	-1.55%
FCF yield	-1.44%
Forward EV/Sales	42.16x
Forward P/S	45.11x
P/B ratio	12.27x
P/S ratio	38.65x
Price / tangible book value	13.05x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-109.34%
EBITDA margin	-98.52%
Gross margin	-66.02%
Operating margin	-109.34%
Pretax margin	-138.55%
Profit margin	-141.43%
Profit per employee	$-670,426
Revenue per employee	$474,043
ROA	-13.26%
ROA (5Y)	6.72%
ROCE	-28.91%
ROE	-39%
ROE (5Y)	22.02%
ROIC	-75.99%
ROIC (5Y)	40.43%
SBC / revenue	20.74%
Tax / revenue	2.87%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	2
Net income growth quarters	1
Net income growth years	2
Revenue growth	-27.62%
Revenue growth (Q)	2.11%
Revenue growth (QoQ)	-62.72%
Revenue growth 3Y	-40.64%
Revenue growth 5Y	-20.51%
Revenue growth quarters	2
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-171M
Depreciation and amortization	$241M
EBIT	$-2.4B
EBITDA	$-2.2B
EPS	$-8.01
FCF per share	$-3.12
Financing cash flow	$611M
Free cash flow	$-1.2B
Free cash flow minus SBC	$-1.7B
Gross profit	$-1.5B
Income taxes	$64M
Investing cash flow	$905M
Net borrowing	$578M
Net cash flow	$443M
Net income	$-3.2B
Operating cash flow minus SBC	$-1.5B
Operating income	$-2.4B
Revenue	$2.2B
Stock-based compensation	$462M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.62
Book value per share	$16.94
Debt / equity	0.19
Goodwill	$52M
Interest coverage	-58
Long-term assets	$5.1B
Long-term liabilities	$1.7B
Net cash (debt)	$5.6B
Net cash / market cap	6.53%
Net cash growth	-16.87%
Net debt / equity	-0.83
Piotroski F-Score	2
Property, plant and equipment	$2.8B
Shareholders' equity	$6.8B
Tangible book value	$6.6B
Tangible book value per share	$16.54
Total assets	$11B
Total cash	$5.1B
Total debt	$1.3B
Total liabilities	$4.2B
WACC	10.16%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.19
Current assets	$5.8B
Current liabilities	$2.5B
Current ratio	2.29
Inventory turnover	14.23
Net working capital	$-1.8B
Quick ratio	2.07
Working capital	$3.3B
Working capital turnover	0.57

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-1.94%
Dividend yield	0%
Shareholder yield	-1.94%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$96.96
1D price change	3.01%
1M price change	7.39%
1M total return	7.39%
1W price change	-11.77%
1W total return	-11.77%
1Y price change	701.13%
1Y return CAGR	702.27%
1Y total return	701.13%
20-day SMA	$211.84
200-day SMA	$84.76
3M price change	283.93%
3M total return	283.93%
3Y price change	197.01%
3Y return CAGR	43.73%
3Y total return	197.01%
50-day SMA	$179.74
50-day SMA vs 200-day SMA	50over200
52-week high	$254.48
52-week high date	2026-10-21
52-week low	$22.28
52-week low date	2025-11-21
5Y price change	-37.34%
5Y return CAGR	-8.93%
5Y total return	-37.34%
6M price change	338.56%
6M total return	338.56%
After-hours change	-0.16%
After-hours close	$214.24
After-hours price	$213.89
All-time high	$497.49
All-time high date	2021-08-10
All-time low	$11.54
All-time low date	2019-08-07
Average true range (ATR)	$21.45
Average volume	19.7M
Beta (1Y)	0.34
Beta (2Y)	0.91
Beta (5Y)	1.09
Change from 52-week high	-15.81%
Change from 52-week low	861.58%
Change from all-time high	-57.07%
Change from all-time low	1,750.78%
Change from open	5.14%
Day's gap	-2.02%
Dollar volume	$2.4B
High price	$218.00
Low price	$202.80
Monthly RSI	79.08
Open price	$203.76
Position in 52-week range	75.26%
Premarket change	-2.15%
Premarket close	$207.97
Premarket price	$203.49
Premarket volume	197.8K
Previous close	$207.97
Price vs 150-day SMA	120.28%
Price vs 20-day SMA	0.82%
Price vs 200-day SMA	152%
Price vs 50-day SMA	18.83%
Relative volume	0.56
RSI	54.82
Sharpe ratio	1.61
Sharpe ratio (3Y)	0.64
Sharpe ratio (5Y)	0.24
Sortino ratio	6.21
Sortino ratio (3Y)	1.75
Sortino ratio (5Y)	0.63
Volume	11M
Weekly RSI	76.02
YTD price change	624.25%
YTD total return	624.25%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	372M
Float percentage	93.17%
Shares change (QoQ)	0.76%
Shares change (YoY)	1.94%
Shares held by insiders	6.74%
Shares held by institutions	80.57%
Shares outstanding	399.2M
Short % of float	8.3%
Short % of shares	7.73%
Short ratio	2 days

Other indicators

Additional ticker metrics that do not fit the primary research groupings.

Metric	Value
Page views	1,059

Deeper analysis on MRNA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this MRNA report

What is the latest published MRNA stock rating?

Moderna Inc. is shown with Hold in the latest published report, analyzed 2026-05-13. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full MRNA analysis?

The full latest published report, analyzed 2026-05-13, lives at /stocks/MRNA/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for MRNA?

The latest published report analyzed 2026-05-13 gives MRNA a fair value of USD 58 and a potential value of USD 79. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the MRNA page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-05-13). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HoldMRNA · Fair value $58.3+9.4%

Read full analysis →

Category	Score	Reading
Valuation	6.0
Management	6.3
Balance Sheet	8.5
Profitability	1.5
Revenue Growth	9.0
Risk Assessment	8.0
Competitive Moat	3.0
Earnings Quality	5.0
Capital Efficiency	2.5

Moderna Inc. (MRNA)

Our latest published analysis: MRNA rated Hold

Price

Financial snapshot

Fair-value bridge

Latest news · MRNA

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All MRNA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Other indicators

Deeper analysis on MRNA

Frequently asked questions

등급 이력